Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer

British Journal of Cancer

Volumn 57, Issue 6, 1988, Pages 608-611

  Baum, M ^b   Brinkley, D M ^b   Dosset, J A ^b   McPherson, K ^b   Jackson, I M ^b   Rubens, R D ^b   Smiddy, F G ^b   Stoll, B A ^b   Wilson, A J ^b   Birch, I H ^b   Palmer, M K ^b  

^a AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY;

BREAST NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMAN; PROGNOSIS; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; TIME FACTORS;

EID: 0023888245     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1988.138     Document Type: Article

References (16)

1. ANONYMOUS (1984). Points of view. Lancet, 2, 1205.
2. CONSENSUS CONFERENCE (1985). Adjuvant therapy for breast cancer. JAMA, 254, 3461.
3. COWAN, S. & LEAKE, R.E. (1984). British interlaboratory quality assessment of steroid receptor assays. Recent results. Cancer Res., 91, 98.
4. COX, D.R. (1972). Regression models and life tables. J. Roy. Statist. Soc. B, 34, 187.
5. KING, R.J.B., BARNES, D.M., HAWKINS, R.A., LEAKE, R.E., MAYNARD, P. V. & ROBERTS, M.M. (1978). Measurement of oestradiol receptors by five institutions on common tissue samples. Br. J. Cancer, 38, 428.
6. KNABBE, C., LIPPMAN, M.E., WAKEFIELD, L.M. & 4 others (1987). Evidence that transforming growth factor B is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48, 417.
7. LAM, H.T.P. (1984). Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Commun., 118, 27.
8. LYKKESFELDT, A.E., LARSEN, J.K., CHRISTENSEN, I.J. & BRIAND, P. (1984). Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. Br. J. Cancer, 49, 717.
9. MARCHETTI, E., QUERZOLI, P., MONCHARMONT, B., PARIKH, I., BAGNI, A. & MARZOLA, A. (1987). Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran coated charcoal method. Fabris G and Nenci I. Cancer Res., 47, 2508.
10. NOLVADEX ADJUVANT TRIAL ORGANISATION (1983a). Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet, 1, 257.
11. NOLVADEX ADJUVANT TRIAL ORGANISATION (1983b). Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet, 2, 450.
12. NOLVADEX ADJUVANT TRIAL ORGANISATION (1985). Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by 'Nolvadex' Adjuvant Trial Organisation. Lancet, 1, 836.
13. O'BRIAN, C.A., LISKAMP, R.M., SOLOMAN, D.H. & WEINSTIN, I.B. (1986). Triphenylethylenes: A new class of protein kinase C inhibitors. J. Natl Cancer Inst., 76, 1243.
14. PETO, R., PIKE, M.C. & ARMITAGE, P. & 7 others. (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 35, 1.
15. SUTHERLAND, R.L., HALL, R.E. & TAYLOR, I.W. (1983). Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res., 43, 3998.
16. SUTHERLAND, R.L., WATTS, C.K. & RUENITZ, P.C. (1986). Definition of two district mechanisms of action of antioestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the oestrogen receptor. Biochem. Biophys. Res. Commun., 140, 523.